Hyper (XKRX:065650) ROCE % : -83.26% (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Hyper ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hyper's annualized ROCE % for the quarter that ended in Mar. 2024 was -83.26%.

Hyper ROCE % Historical Data

The historical data trend for Hyper's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyper ROCE % Chart

Hyper Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-9.25

-8.13

-18.43

-23.51

-2.77

Hyper Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-2.60	-79.63	1.97	79.95	-83.26

Hyper ROCE % Calculation

Hyper's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1274.464	/	( ( (55752.674 - 2358.326)	+	(55785.623 - 17197.12) )	/ 2 )
	=	-1274.464	/	( (53394.348	+	38588.503)	/ 2 )
	=	-1274.464	/	45991.4255
	=	-2.77 %

Hyper's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-34838.656	/	( ( (55785.623 - 17197.12)	+	(52902.524 - 7805.114) )	/ 2 )
	=	-34838.656	/	( ( 38588.503	+	45097.41 )	/ 2 )
	=	-34838.656	/	41842.9565
	=	-83.26 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Hyper (XKRX:065650) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hyper ROCE % Related Terms

Thank you for viewing the detailed overview of Hyper's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyper (XKRX:065650) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyper Corporation Inc (XKRX:065650) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Woolim A-1401, 583, Yangcheon-ro, Gangseo-gu, Seoul, KOR, 07547

Website

http://www.medifron.com

Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.

Hyper (XKRX:065650) Headlines

No Headlines